On August 7, Twist Bioscience Corp rose 5.43% in regular trading, trading at $114.78/share, with turnover of $18.7 million. The stock continued its rebound momentum following the release of strong fiscal Q3 results and forward guidance.

The company reported fiscal Q3 revenue of $118.4 million, representing 23.2% year-over-year growth and beating the analyst consensus estimate of $114.5 million. More critically, the company raised its full-year revenue guidance to $456-$457 million and projected Q4 revenue of $123-$124 million, significantly above the FactSet consensus of $117.4 million. While EPS of -$0.56 missed the -$0.50 estimate, the robust top-line growth and upbeat forward outlook continued to bolster investor confidence in the company's business expansion trajectory.

Since the earnings release on August 3, the stock has experienced volatile trading with sharp multi-directional swings, initially dropping over 9% before recovering more than 6%. Evercore ISI had previously downgraded the stock to In Line in July while raising the price target to $102, reflecting ongoing debate between high valuation and profitability concerns.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)